Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer

PURPOSE: The NeoSphere trial evaluated pertuzumab in the neoadjuvant setting [early breast cancer (EBC)] with pathological complete response (pCR) as the primary efficacy end point. This analysis of pertuzumab aimed to (1) compare its pharmacokinetics (PK) in patients with EBC versus advanced cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Quartino, Angelica L., Li, Hanbin, Jin, Jin Y., Wada, D. Russell, Benyunes, Mark C., McNally, Virginia, Viganò, Lucia, Nijem, Ihsan, Lum, Bert L., Garg, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306091/
https://www.ncbi.nlm.nih.gov/pubmed/28074265
http://dx.doi.org/10.1007/s00280-016-3218-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306091/
https://www.ncbi.nlm.nih.gov/pubmed/28074265
http://dx.doi.org/10.1007/s00280-016-3218-0

Ejemplares similares